LIXT
Lixte Biotechnology·NASDAQ
--
--(--)
--
--(--)
7.56 / 10
Outperform
Fund flow analysis is positive with a 7.56/10 score, reflecting overall inflow across block, small, medium, large, and extra-large transactions. Although no analyst ratings are available (ana_eval = -1), the strong fund inflow and positive sentiment complement the technical strength, suggesting market interest despite fundamental drawbacks.
Fund Flow Rating
What is the analyst consensus for LIXT?
- LIXT holds a Neutral analyst rating, with 0% of experts assigning a Hold grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 7.56/10 (Outperform).
